Page 101 - 88_01
P. 101
ANALES 44. Bueno H, Bardají A, Patrignani P, Martín-Merino E, García-Rodríguez
RANF LA. Use of Non- Steroidal Antiinflammatory Drugs and Type-Specific
Risk of Acute Coronary Syndrome. Am J Cardiol.
www.analesranf.com 2010;105(8):1102–6. Among chronic opioid and cyclooxyge-
nase-2 users compared with a general population cohort. Phar-
Aguado J, Garcia Rodriguez LA. The use of selective cyclooxygenase- macoepidemiol Drug Saf. 2011;20:754–62.
2 inhibitors and the risk of acute myocardial infarction in Saskat-
chewan, Canada. Pharmacoepidemiol Drug Saf. 46. Caughey GE, Roughead EE, Pratt N, Killer G, Gilbert AL. Stroke risk
2009;18:1016–25. and NSAIDs: An australian population-based study. Med J Aust.
32. Abraham NS, EL-Serag HB, Hartman C, Richardson P, Deswal 2011;195(9):525–9.
A. Cyclooxygenase-2 cerebrovascular accident. Aliment Pharmacol
Ther. 2007;25(8):913–24. 47. Chan AT, Manson JE, Albert CM, Chae CU, Rexrode KM, Curhan GC,
33. Abraham NS, Castillo DL, Hartman C. National mortality following et al.. Nonsteroidal antiinflammatory drugs, acetaminophen, and
upper gastrointestinal or cardiovascular events in older veterans with the risk of cardiovascular events. Circulation. 2006;113(12):1578–
recent nonsteroidal anti-inflammatory drug use. Aliment Pharmacol 87.
Ther. 2008;28(1):97–106.
34. Andersohn F, Suissa S, Garbe E. Use of first- and second-generation 48. Chang CH, Shau WY, Kuo CW, Chen ST, Lai MS. Increased risk of
cyclooxygenase-2- selective nonsteroidal antiinflammatory drugs stroke associated with nonsteroidal anti-inflammatory drugs: A
and risk of acute myocardial infarction. Circulation. nationwide case-crossover study. Stroke. 2010;41(9):1884–
2006;113(16):1950–7. 90.
35. Andersohn F, Schade R, Suissa S, Garbe E. Cyclooxygenase-2 selec-
tive nonsteroidal anti- inflammatory drugs and the risk of ischemic 49. Chao T-F, Liu C-J, Chen S-J, Wang K-L, Lin Y-J, Chang S-L, et al..
stroke: A nested case-control study. Stroke. 2006;37(7):1725–30. The association between the use of non-steroidal anti-inflammatory
36. Bäck M, Yin L, Ingelsson E. Cyclooxygenase-2 inhibitors and cardio- drugs and atrial fibrillation: A nationwide case– control study. Int
vascular risk in a nation- wide cohort study after the withdrawal of J Cardiol. 2013;168(1):312–6.
rofecoxib. Eur Heart J. 2012;33(15):1928–33.
37. Barthélémy O, Limbourg T, Collet JP, Beygui F, Silvain J, Bellemain- 50. Choi NK, Park BJ, Jeong SW, Yu KH, Yoon BW. Nonaspirin nonste-
Appaix A, et al.. Impact of non-steroidal anti-inflammatory drugs roidal anti-inflammatory drugs and hemorrhagic stroke risk: The
(NSAIDs) on cardiovascular outcomes in patients with stable athe- acute brain bleeding analysis study. Stroke. 2008;39(3):845–
rothrombosis or multiple risk factors. Int J Cardiol. 9.
2013;163(3):266–71.
38. Hippisley-cox J, Coupland C. Risk of myocardial infarction in 51. Cunnington M, Webb D, Qizilbash N, MRCP, DPhil, Blum D, et al..
patients taking cyclo- oxygenase-2 inhibitors or conventional non- Risk of ischaemic cardiovascular events from selective cyclooxige-
steroidal anti-inflammatory drugs: population based nested case- nase-2 inhibitors in osteoarthritis. Pharmacoepidemiol Drug Saf.
control analysis. BMJ. 2005;330(7504):1336. 2008;17:601–8.
39. Battelli D, Riccardi A, Piscaglia A., Stefanelli ML, Mussoni L, Zani A,
et al.. Analgesic, antiulcer, antithrombotic drugs and organ damage: 52. de Abajo FJ, Gil MJ, García Poza P, Bryant V, Oliva B, Timoner J, et
a population-based case-control study. MInerva MEd. al.. Risk of nonfatal acute myocardial infarction associated with
2015;106(6):323–31. nonsteroidal antiinflammatory drugs, non-narcotic analgesics and
40. Bavry AA, Thomas F, Allison M, Johnson KC, Howard B V., Hlatky other drugs used in osteoarthritis: a nested case-control study. Phar-
M, et al.. Nonsteroidal anti-inflammatory drugs and cardiovascular macoepidemiol Drug Saf. 2014;23:1128–38.
outcomes in women: Results from the women’s health initiative.
Circ Cardiovasc Qual Outcomes. 2014;7(4):603–10. 53. De Vries F, Setakis E, Van Staa TP. Concomitant use of ibuprofen
41. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk and paracetamol and the risk of major clinical safety outcomes. Br
of hospitalization for congestive heart failure in rheumatoid arthritis. J Clin Pharmacol. 2010;70(3):429–38.
Rheumatology. 2005;44(5):677–80.
42. Biere-Rafi S. Non-steroidal anti-inflammatory drugs and risk 54. Feenstra J, Heerdink ER, Grobbee DE, Stricker BHC. Association of
of pulmonary embolism. Pharmacoepidemiol Drug Saf. nonsteroidal anti- inflammatory drugs with first occurrence of heart
2011;20:635–42. failure and with relapsing heart failure: the Rotterdam Study. Arch
43. Brophy JM, Levesque LE, Zhang B. The coronary risk of cyclo-oxy- Intern Med. 2002;162(3):265–70.
genase-2 inhibitors in patients with a previous myocardial infarction.
Heart. 2005;93(2):189–94. 55. Fischer LM, Schlienger RG, Matter CM, Jick H, Meier CR. Current use
of nonsteroidal antiinflammatory drugs and the risk of acute
myocardial infarction. Pharmacotherapy. 2005;25(4):503–10.
56. Fosbøl EL, Folke F, Jacobsen S, Rasmussen JN, Sørensen R, Schramm
TK, et al.. Cause- specific cardiovascular risk associated with
nonsteroidal antiinflammatory drugs among healthy individuals.
Análisis y evaluación del riesgo cardiovascular y gastrointestinal de los antiinfla- 99
matorios no esteroideos inhibidores selectivos y no selectivos de ciclooxigenasa
Antonio Margo
An. Real Acad. Farm.Vol. 88. nº 1 (2022) · pp. 85-103
